Pursuant to Regulation 34 of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015, please find enclosed the Notice of Extraordinary General Meeting to be held on 11/August/2025 ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Sudarshan Pharma Industries has called an Extraordinary General Meeting on 11 August 2025 at 1:00 p.m. (via video conferencing) to seek shareholder approval for issuing securities worth up to ₹1,500 Crores. The proposed instruments include equity shares (face value ₹1), Global Depository Receipts (GDRs), Foreign Currency Convertible Bonds (FCCBs), and convertible or non-convertible debentures with warrants. These can be raised through a public issue, preferential issue, qualified institutional placement (QIP), private placement, or a combination, in domestic and/or international markets, in one or more tranches. For a QIP, pricing will follow the SEBI ICDR formula with up to a 5% discount, and the issue must close within 365 days. The company plans to use the proceeds for growth, expansion, capital expenditure, and acquisitions in India and overseas, along with general corporate purposes.
If approved, this could lead to significant equity dilution for existing shareholders since ₹1,500 Crores is a very large raise relative to typical small-cap pharma companies. Shareholders should weigh the dilution risk against the stated growth and acquisition plans, and vote before the 10 August 2025 e-voting deadline.